Dosar de subiect

Altele

Lilly Faces HSBC Sell Rating Amid Weight Loss Drug Price Cut Expectations

Primul articol: 17 mar. 2026, 15:59 | Ultima actualizare: 17 mar. 2026, 15:59 | 1 sursa | 1 articol
#pharmaceuticals#weightlossdrugs#stockmarket

Mai multe surse. Mai putina manipulare.

Analiza editoriala

Bazat pe 1 sursa, 1 articol

HSBC's decision to issue a sell rating for Lilly reflects growing concerns about the company's future profitability in the face of potential price reductions for its weight loss medications. The weight loss drug market is becoming increasingly competitive, with multiple companies vying for market share. This increased competition is expected to put downward pressure on prices, potentially impacting Lilly's revenue and earnings.

Articole despre acest subiect

Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts Foto: Bloomberg
Bloomberg English Angel Adegbesan 17 mar. 2026, 15:59 (acum 1 zi)

Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts

Eli Lilly & Co. shares dip after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are over inflated.

Citeste pe Bloomberg →